高血压影响慢性淋巴细胞白血病的生存与治疗
这项丹麦全国性队列研究(2008-2022年)纳入新发慢性淋巴细胞白血病(CLL)患者,分析高血压与CLL诊断后及一线治疗生存的关联。CLL诊断时高血压患病率为46%,高血压与CLL诊断后总生存期缩短(HR 1.10;95%CI 1.00-1.20)及一线治疗后总生存期缩短(HR 1.48;95%CI 1.18-1.86)相关,主要由感染和心脑血管死亡驱动;<75岁患者中关联更明显。
要点
- CLL诊断时高血压患病率46%,与一般人群的45%相近。
- 高血压与CLL诊断后及一线治疗后的总生存期缩短相关。
- <75岁合并高血压的CLL患者预后更差,需加强预防健康管理。
核心结论
- 高血压是CLL诊断后及一线治疗后总生存期缩短的关联因素,主要由感染和心脑血管死亡驱动。
- 高血压在CLL患者中未比无CLL个体带来更高的额外风险(HR 0.89;95%CI 0.79-1.02)。
研究设计与样本
- 丹麦全国性队列研究,纳入2008-2022年新发CLL患者,随访至2022年。
- 采用Cox比例风险回归分析生存,Aalen-Johansen估计累积发病率。
主要发现
- CLL诊断时高血压患病率为46%,一般人群为45%。
- 高血压与CLL诊断后总生存期缩短相关(HR 1.10;95%CI 1.00-1.20)。
- 高血压与一线治疗后总生存期缩短相关(HR 1.48;95%CI 1.18-1.86)。
- <75岁患者中,诊断后(HR 1.43;95%CI 1.25-1.64)及一线治疗后(HR 1.89;95%CI 1.34-2.66)关联更明显。
- 接受BTK抑制剂治疗的高血压患者总生存期有更差趋势(HR 1.97;95%CI 0.90-4.34)。
临床怎么用
- 对<75岁合并高血压的CLL患者应加强关注,鼓励定期初级保健随访并坚持预防性健康措施。
- 高血压及相关共病在CLL诊断后仍对生存有重要影响,应纳入整体管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertension is the most common comorbidity in patients with chronic lymphocytic leukemia (CLL), but its impact on the disease course of CLL remains poorly understood. In this nationwide cohort study of Danish patients with incident CLL (2008-2022), we examined the association between hypertension and survival from CLL diagnosis and treatment, and compare with the general population. Cox proportional hazard regression was applied for survival analyses, and the Aalen-Johansen estimator for cumulated incidence. At diagnosis of CLL, the hypertension prevalence was 46% in the CLL cohort and 45% in the general population. Hypertension was associated with shorter overall survival (OS) following CLL diagnosis (hazard ratio [HR], 1.10; 95% confidence interval [CI], 1.00-1.20) and first-line treatment (HR, 1.48; 95% CI, 1.18-1.86), primarily driven by infections and cardiocerebrovascular causes of death. The difference was seen for patients aged <75 years both following diagnosis (HR, 1.43; 95% CI, 1.25-1.64) and first-line treatment (HR, 1.89; 95% CI, 1.34-2.66). For patients treated with Bruton tyrosine kinase inhibitors, we observed a trend toward poorer OS in patients with hypertension (HR, 1.97; 95% CI, 0.90-4.34). No interaction between CLL in general and hypertension was observed (HR, 0.89; 95% CI, 0.79-1.02), meaning that hypertension did not confer a higher additional risk in patients with CLL than in individuals without CLL. This study identifies an important subgroup of patients with CLL aged <75 years with coexisting hypertension who have a poorer prognosis. Our findings support encouraging patients to maintain regular contact with primary care and adhere to preventative health measures, as hypertension and related comorbidities remain important for survival even after CLL diagnosis.
引用
- Vainer N, Brieghel C, Rostgaard K, et al. Hypertension affects survival and treatment in chronic lymphocytic leukemia. Blood Adv. 2026. PMID: 41604617. doi:10.1182/bloodadvances.2025018771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。